Oral Cancer Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The oral cancer treatment market size has grown strongly in recent years. It will grow from $2.04 billion in 2024 to $2.2 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to interdisciplinary treatment approaches, screening programs implementation, improvements in palliative care, reconstructive surgery innovations, clinical trial discoveries.

The oral cancer treatment market size is expected to see strong growth in the next few years. It will grow to $2.86 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to regulatory support for innovative therapies, advancements in biomarker research, expanding therapeutic options, improved screening and early detection, telemedicine and remote monitoring. Major trends in the forecast period include global epidemiological changes, regulatory changes and approvals, rising awareness and early detection campaigns, patient-centric care, adjuvant therapies.

The increasing consumption of tobacco is projected to drive the growth of the oral cancer treatment market in the future. Tobacco, derived from the leaves of Nicotiana tabacum and other plants in the Nicotiana genus, contains harmful substances, carcinogens, and nicotine, which are associated with a heightened risk of various cancers, including oral cancer. For example, in December 2023, the National Health Service, a government department in the UK, reported an estimated 408,700 hospital admissions related to smoking in the 2022-23 period, up from 389,800 in 2021-22, reflecting a rise of 4.8%. Therefore, the rising tobacco consumption is fueling the growth of the oral cancer treatment market.

The growing prevalence of oral cancer is expected to be a key factor propelling the oral cancer treatment market. Oral cancer, characterized by uncontrolled cell growth and invasion affecting oral cavity tissues, is typically treated through surgical resection, radiation therapy, and chemotherapy, depending on the disease's stage. In 2022, the American Cancer Society reported approximately 54,540 new cases of oral cavity or oropharyngeal cancer each year, leading to approximately 11,580 deaths annually. Consequently, the rising incidence of oral cancer stands as a driving force for the growth of the oral cancer treatment market.

Major companies in the oral cancer treatment market are focusing on developing innovative solutions such as CancerDetect to enhance their market profitability. CancerDetect, a screening test for mouth and throat cancer, was launched by Viome Life Sciences Inc. in August 2022. This at-home test aims to detect early-stage oral and throat cancer biomarkers, particularly oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC).

In August 2022, Merck & Co. Inc., a leading pharmaceutical company in oral cancer drug development, collaborated with Orna Therapeutics. This collaboration seeks to accelerate the development of RNA therapies, leveraging the combined expertise of both companies to provide new treatment options for patients. The partnership with Orna Therapeutics aligns with Merck & Co.'s commitment to advancing innovative cancer treatments and improving patient outcomes. Orna Therapeutics, a biotech firm in the United States, specializes in developing treatments for various illnesses, including cancer.

Major companies operating in the oral cancer treatment market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co., AbbVie Inc., Novartis AG, Bayer AG, Sanofi-Aventis LLC, Bristol Myers Squibb, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG., Viatris Inc., Teva Pharmaceuticals Industries Ltd., MD Anderson Cancer Center, Bausch Health Companies Inc., Memorial Sloan Kettering Cancer Center, Aurobindo Pharma Limited, Cipla Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Fred Hutchinson Cancer Research Center, Fresenius Kabi AG, Innovent Biologics Inc., Genentech Inc., Intas Pharmaceuticals Ltd., Ascendis Pharma A/S, Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the oral cancer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral cancer treatment market consists of revenues earned by entities by providing services such as diagnosis and staging, surgical services, radiation therapy, chemotherapy and targeted therapy, immunotherapy, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral cancer treatment market also includes sales of biopsy tools, imaging equipment, endoscopes, surgical instruments, radiation machines, cisplatin, docetaxel, methotrexate, bleomycin sulfate, and pembrolizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Oral cancer treatment encompasses medical interventions and therapies aimed at diagnosing, managing, and potentially curing cancer that develops in the oral cavity or oral tissues. The chosen treatment approach is contingent upon factors such as the type, stage, and location of the cancer, as well as the overall health of the patient.

The primary types of oral cancer treatment are designed for conditions such as oral squamous cell carcinoma, oral verrucous carcinoma, mucoepidermoid carcinoma, and oral cavity lymphomas. Oral squamous cell carcinoma originates in the squamous cells lining the oral cavity, including the lips, tongue, inner lining of the cheeks, and gums. Various therapeutic modalities include chemotherapy, radiation therapy, and biological therapy, administered through oral, injectable, and other routes. The diverse end users include hospitals, homecare, specialty clinics, and others.

The oral cancer treatment market research report is one of a series of new reports that provides oral cancer treatment market statistics, including oral cancer treatment industry global market size, regional shares, competitors with an oral cancer treatment market share, detailed oral cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the oral cancer treatment industry. This oral cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.